hexenoyl cap raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
== Max Jaffe == Max Jaffe was a distinguished 19th-century German biochemist, pathologist, pharmacologist, and professor. He was born on July 25, 1841, in what was formerly Grünberg, Silesia and is now Zielona Góra, Poland. While attending medical school at the University of Berlin, he studied under Ludwig Traube and Wilhelm Kühne. Afterward, he worked as an assistant in a medical clinic in Königsberg. There, he co-authored a paper on putrid sputum with Ernst Viktor von Leyden that led to the discovery of certain characteristic putrid processes in the lungs. After earning his degree in internal medicine, he served in the Franco-Prussian War and was decorated with the Iron Cross Second Class. The title of Extraordinary Professor of Medicinal Chemistry was awarded to him in 1872 and the following year he became the first Ordinary Professor of Pharmacology at the University of Königsberg. He was promoted to director of the Laboratory for Medical Chemistry and Experimental Pharmacology in 1878 and became a member of the Deutsche Akademie der Naturforscher Leopoldina in 1882. Aside from studying creatinine, he is also known for discovering urobilin and urobilinogen in urine and found that these compounds originated in bile. He died on October 26, 1911, in Berlin and is buried in the Weißensee Cemetery.
According to physician Robert Barouki (2023), research on women's health has historically been limited by social bias and an emphasis on male physiology. French geneticist Claudine Junien noted in 2016 that France lagged behind other countries in integrating sex-based biological differences in research and treatment, though attention to gender parity in healthcare was increasing.
=== Cardiac === In dermatomyositis, patients can develop myocarditis and cardiac conduction system abnormalities which may be detected if the patient undergoes special testing. However, these abnormalities typically have no symptoms or clinical consequences. More rarely, these abnormalities can cause greater issues and lead to arrhythmias, heart failure, or damage to heart valves. For those dermatomyositis patients who do have cardiac symptoms caused by the disease, their clinical course may be much worse than usual.
== Regulation and oversight == Some governmental bodies, including the European Union as well as NIOSH and the United States Environmental Protection Agency (EPA), regulate concentrations of PAHs in air, water, and soil. The European Commission has restricted concentrations of 8 carcinogenic PAHs in consumer products that contact the skin or mouth. Priority polycyclic aromatic hydrocarbons identified by the US EPA, the US Agency for Toxic Substances and Disease Registry (ATSDR), and the European Food Safety Authority (EFSA) due to their carcinogenicity or genotoxicity and/or ability to be monitored are the following:
The associated enzymes are subject to regulation via feedback inhibition and/or repression at the genetic level. As is typical in highly branched metabolic pathways, additional regulation at each branch point of the pathway. This type of regulatory scheme allows control over the total flux of the aspartate pathway in addition to the total flux of individual amino acids. The aspartate pathway uses L-aspartic acid as the precursor for the biosynthesis of one-fourth of the building block amino acids.
Sources: en.wikipedia.org
Figure 3 shows B versus R∗ for the rough pipe data of Nikuradse, Shockling, and Langelandsvik. In this view, the data at different roughness ratio ε/D fall together when plotted against R∗, demonstrating scaling in the variable R∗. The following features are present:
(registration required) Shahid, I. (2000). "Tanūkh". In Bearman, P. J.; Bianquis, Th.; Bosworth, C. E.; van Donzel, E. & Heinrichs, W. P. (eds.). The Encyclopaedia of Islam, Second Edition. Volume X: T–U. Leiden: E. J. Brill. pp. 190–192. ISBN 978-90-04-11211-7. Sourdel, D. (1971). "Ḥawrān". In Lewis, B.; Ménage, V.L.; Pellat, Ch.; Schacht, J. (eds.). The Encyclopaedia of Islam, New Edition. Vol. III: H–Iram. Leiden: E.J. Brill. pp. 292–293. ISBN 90-04-08118-6. Stone, Christopher (2008). Popular Culture and Nationalism in Lebanon: The Fairouz and Rahbani Nation. Abingdon, Oxon and New York: Routledge. ISBN 978-0-415-77273-0.
=== Interest in William James === During his first trip to the United States with Freud, Jung was introduced to the elder philosopher and psychologist William James, known as the "Father of American psychology," whose ideas Jung would incorporate into his own work. Jung connected with James around their mutual interests in mysticism, spiritualism and psychical phenomena. James wrote to a friend after the conference stating Jung "left a favorable impression," while "his views of Freud were mixed." James died about eleven months later. The ideas of both Jung and James, on topics including hopelessness, self-surrender, and spiritual experiences, were influential in the development and founding of the international altruistic, spiritual movement Alcoholics Anonymous on 10 June 1935, in Akron, Ohio, a quarter of a century after James' death and in Jung's sixtieth year.
Dover grew further after the Norman invasion of 1066 as a member of the Confederation of Cinque Ports. After the martyrdom of Archbishop Thomas Becket at Canterbury Cathedral in 1170, Dover flourished as the only designated port of entry for foreign pilgrims and as a point of departure for the third and subsequent crusades. Following Edward III's success at the Battle of Sluys in 1340, a large defensive wall was built around the town. Although few concerted attempts to manage the shingle deposits blocking the harbour entrance were made during the late Middle Ages, a short pier and two defensive towers were constructed at the port in years immediately prior to Henry VIII's departure to the royal summit known as the Field of the Cloth of Gold in 1520.
Sources: en.wikipedia.org
== Surgical rhinoplasty == There is limited evidence that a single dose of corticosteroids decreases oedema and bleeding first two days post operation but the difference is not maintained after this. Swelling and edema can take at least 1-year to diminish. Certain adjuncts, including fat grafting may help quicken the time to edema and bruising resolution.
The three substrates of this enzyme are saccharopine, oxidised nicotinamide adenine dinucleotide phosphate (NADP+), and water. Its products are L-lysine, α-ketoglutaric acid, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is N6-(L-1,3-dicarboxypropyl)-L-lysine:NADP+ oxidoreductase (L-lysine-forming). Other names in common use include lysine-2-oxoglutarate reductase, lysine-ketoglutarate reductase, L-lysine-alpha-ketoglutarate reductase, lysine:alpha-ketoglutarate:TPNH oxidoreductase, (epsilon-N-[gultaryl-2]-L-lysine forming), saccharopine (nicotinamide adenine dinucleotide phosphate,, lysine-forming) dehydrogenase, 6-N-(L-1,3-dicarboxypropyl)-L-lysine:NADP+ oxidoreductase, and (L-lysine-forming). This enzyme participates in lysine biosynthesis and lysine degradation.
=== Stable interactions vs. transient interactions === Stable interactions involve proteins that interact for a long time, taking part of permanent complexes as subunits, in order to carry out functional roles. These are usually the case of homo-oligomers (e.g. cytochrome c), and some hetero-oligomeric proteins, as the subunits of ATPase. On the other hand, a protein may interact briefly and in a reversible manner with other proteins in only certain cellular contexts – cell type, cell cycle stage, external factors, presence of other binding proteins, etc. – as it happens with most of the proteins involved in biochemical cascades. These are called transient interactions. For example, some G protein–coupled receptors only transiently bind to Gi/o proteins when they are activated by extracellular ligands, while some Gq-coupled receptors, such as muscarinic receptor M3, pre-couple with Gq proteins prior to the receptor-ligand binding. Interactions between intrinsically disordered protein regions to globular protein domains (i.e. MoRFs) are transient interactions.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.